Recombinant Human CD40L/CD154 protein (His Tag)
ED50
17-68 ng/mL
Species
Human
Purity
>95 %, SDS-PAGE
GeneID
959
Accession
P29965
验证数据展示
Technical Specifications
Purity | >95 %, SDS-PAGE |
Endotoxin Level | <1.0 EU/μg protein, LAL method |
Biological Activity |
Immobilized Human CD40L (His tag) at 2 μg/mL (100 μL/well) can bind Human CD40 (Myc tag, His tag) with a linear range of 17-68 ng/mL. |
Source | HEK293-derived Human CD40L protein Met113-Leu261 (Accession# P29965) with a His tag at the N-terminus. |
Predicted Molecular Mass | 17 kDa |
SDS-PAGE | 17-19 kDa, reducing (R) conditions |
Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
Storage |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
The CD40 ligand (CD40L), also known as TRAP or CD154, is a member of the TNF superfamily of ligands. CD40L is primarily expressed on activated CD4+ T cells and on a small proportion of CD8+ T cells and platelets. It binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. It has been suggested that CD40/CD40L interactions regulate oxidative stress and affect various signaling pathways in both the immunological and the cardiovascular systems. The CD40/CD40L system is also involved in tumorigenesis. Its expression is tightly regulated, and abnormal levels of CD40L are associated with the pathogenesis of atheromatous plaque destabilization and thrombotic events. Multiple mutations in CD40LG gene have been identified that are associated with hyper-IgM immunodeficiency syndrome type 1.
References:
1. Elgueta R. et al. (2009). Immunol Rev. 229(1):152-172. 2. Rizvi M. et al. (2008). Trends Mol Med. 14(12):530-538. 3. Michel N A. et al. (2017). Front Cardiovasc Med. 4:40.